check_circleStudy Completed

Metastatic castration-resistant prostate cancer (mCRPC)

Bayer Identifier:

18499

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

EU CT Number:

Not Available
Analysis of Care for Patients with Castration-Resistant Prostate Cancer (CRPC)

Trial purpose

A retrospective secondary data analysis on clinical characteristics, treatment patterns and treatment costs, especially to identify Xofigo’s position in real life treatment pathway of CRPC patients.

Key Participants Requirements

Sex

Male

Age

18 - N/A
  • - All patients with a final diagnosis of mCRPC (=indication for the treatment with Xofigo) archived in ContraCare’s reimbursement database

Trial summary

Enrollment Goal
152
Trial Dates
December 2015 - January 2016
Phase
N/A
Could I Receive a placebo
N/A
Products
Xofigo (Radium-223 dichloride, BAY88-8223)
Accepts Healthy Volunteer
No

Primary Outcome

  • Treatment duration of Xofigo and previous mCRPC therapies including
    enhanced_encryption
    Safety Issue:
    No
  • Sequence of mCRPC treatments
    enhanced_encryption
    Safety Issue:
    No

Secondary Outcome

  • Time to treatment with Xofigo
    enhanced_encryption
    Safety Issue:
    No
  • Health insurance decision on the reimbursement of a Xofigo treatment
    enhanced_encryption
    Safety Issue:
    No
  • Hospitalization
    Type of Intervention, Time point & duration of intervention, Costs of intervention
    enhanced_encryption
    Safety Issue:
    No

Trial design

Analysis of Care for Patients with Castration-Resistant Prostate Cancer (CRPC) treated with Xofigo in Germany
Trial Type
Observational
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.